Cargando…

Strategies of drug companies to optimize the sales of their psychiatric drugs

Detalles Bibliográficos
Autor principal:	Whitaker, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332913/ http://dx.doi.org/10.1186/1471-244X-7-S1-S90

Ejemplares similares

Is learning drugs the same as learning non-drugs?
por: Brown, Robert D, et al.
Publicado: (2008)

A company experience of the first MoCA pilot project
por: Hughes-Wilson, Wills
Publicado: (2014)

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
por: Tay-Teo, Kiu, et al.
Publicado: (2019)

Forecasting Sales at Ska Brewing Company
por: Drake, Matthew
Publicado: (2014)

The global challenge of antimalarial drug resistance
por: Ringwald, Pascal, et al.
Publicado: (2012)

MOH Drug SCM Strategy Development: a means to identify human resource training needs in Indonesia
por: Sosialina, Engko, et al.
Publicado: (2014)

Pharmacokinetic–pharmacodynamic modeling considering spinal and peripheral actions of nonsteroidal antiinflammatory drugs to optimize the treatment of inflammation-induced pain
por: Castañeda-Hernández, G, et al.
Publicado: (2004)

Chemoinformatics in drug development
por: Groom, Colin R
Publicado: (2012)

Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T-cells and the influence of Programmed Death-1 on effector T-cell function
por: Gibson, Andrew, et al.
Publicado: (2014)

Coercion and undue influence in decisions to participate in psychiatric research – methodological issues
por: Klitzman, Robert
Publicado: (2007)

Hepatitis C new drugs
por: Wedemeyer, H
Publicado: (2010)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance
por: Wainberg, Mark A
Publicado: (2011)

Drug-specific in vitro release of IFN-gamma in patients with delayed cutaneuos drug hypersensitivity reactions
por: Porebski, Grzegorz, et al.
Publicado: (2015)

Urbanisation as a risk indicator for complex psychiatric disorders and forced admissions
por: Schoevers, Robert, et al.
Publicado: (2007)

New research on psychiatric advance directives
por: Swartz, Marvin, et al.
Publicado: (2007)

Psychiatric paternalism between Scylla and Charybdis
por: Schöne-Seifert, Bettina
Publicado: (2007)

Mass culture of coercive psychiatric confinement
por: Chase, Anthony
Publicado: (2007)

Professional experiences of accessing cancer drugs in the NHS: the introduction of the Cancer Drugs Fund, the individual versus the population
por: Chamberlain, Charlotte, et al.
Publicado: (2014)

Benchmarking psychiatric intensive care units (PICU) in a metropolitan area
por: van Wijk, Cecile Gijsbers, et al.
Publicado: (2007)

Molecular modeling of lipid drug formulations
por: Birru, Woldeamanuel A, et al.
Publicado: (2012)

Drug discovery in the p53 pathway
por: Lane, DP, et al.
Publicado: (2000)

Targeting protein dynamics in drug design
por: Wade, Rebecca C
Publicado: (2013)

Go with the flow and accessorize your drugs
por: Schneider, Gisbert
Publicado: (2014)

The "nocebo effect" in drug hypersensitivity diagnosis
por: Bommarito, Luisa, et al.
Publicado: (2014)

Mechanisms that limit proliferative potential of drug-specific LTT in drug-induced severe cutaneous adverse reaction patients
por: Valeyrie-Allanore, Laurence, et al.
Publicado: (2014)

The Sale of Drugs in Calcutta
Publicado: (1880)

The Sale of Poisonous Drugs
Publicado: (1881)

Role of animal models in oncology drug discovery
por: Kumar, R
Publicado: (2003)

On the validity of popular assumptions in computational drug design
por: Klebe, Gerhard
Publicado: (2011)

Towards a patient-based drug discovery
por: Schreiber, Stuart L
Publicado: (2012)

Cutaneous adverse drug reactions induced by Oxcarbazepine
por: Hsiao, Yi-Hsin, et al.
Publicado: (2014)

Clinical trials in drug development: the Brazilian experience
por: de Morais, Odorico
Publicado: (2014)

New open drug activity data at EBI
por: Steinbeck, C, et al.
Publicado: (2009)

Proposal for a risk management axis in psychiatric classifications
por: Mellsop, Graham
Publicado: (2007)

Coercion and psychiatric rehabilitation: a conceptual and ethical analysis
por: Rudnick, Abraham
Publicado: (2007)

Coercive measures in Spanish psychiatric units (EUNOMIA-study)
por: Mayoral, Fermín, et al.
Publicado: (2007)

The role of systems modeling in drug discovery and predictive health
por: Voit, Eberhard O
Publicado: (2010)

Anti-epileptic drug harms: issues for meta-analysis
por: Smith, Catrin Tudur, et al.
Publicado: (2011)

Management of chronic sensitization, from drugs to physical therapy
por: Roussel, Nathalie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_268varnh0jfho5fllsj9204279